Ocugen investor relations material
Listen to the latest call from Ocugen
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure blindness diseases. The company's lead product candidate is OCUL-001, an adeno-associated virus vector-based gene therapy for the treatment of wet age-related macular degeneration. The company is also engaged in the discovery, design, development and clinical trial advancement of additional AAV and complementary non-AAV gene therapies for retinal diseases, including EIPAO-203 and EPAC1. The company is headquartered in Malvern, Pennsylvania.